Profile data is unavailable for this security.
About the company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
- Revenue in USD (TTM)17.49m
- Net income in USD-78.50m
- Incorporated2020
- Employees136.00
- LocationLiquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
- Phone+1 (919) 328-4400
- Fax+1 (919) 328-4402
- Websitehttps://www.liquidia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 924.20m | 296.00 | -- | 8.73 | -- | 15.51 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 931.64m | 309.00 | -- | 1.25 | -- | 26.37 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Praxis Precision Medicines Inc | 2.45m | -123.28m | 933.06m | 82.00 | -- | 6.88 | -- | 381.31 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 933.24m | 284.00 | -- | -- | -- | 22.43 | -4.45 | -4.45 | 1.08 | -- | -- | -- | -- | 146,514.10 | -- | -29.45 | -- | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | -- | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Tyra Biosciences Inc | 0.00 | -69.13m | 937.55m | 49.00 | -- | 3.76 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Immunome Inc | 14.02m | -106.81m | 944.11m | 55.00 | -- | 5.68 | -- | 67.35 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
ARS Pharmaceuticals Inc | 30.00k | -54.37m | 944.72m | 24.00 | -- | 4.07 | -- | 31,490.68 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Cassava Sciences Inc | 0.00 | -97.22m | 953.57m | 29.00 | -- | 6.77 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Ocular Therapeutix Inc | 58.44m | -80.74m | 954.66m | 267.00 | -- | 7.78 | -- | 16.34 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Innoviva Inc | 310.46m | 179.72m | 961.06m | 112.00 | 6.78 | 1.43 | 4.46 | 3.10 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Liquidia Corp | 17.49m | -78.50m | 972.40m | 136.00 | -- | 18.56 | -- | 55.60 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
MacroGenics Inc | 58.75m | -9.06m | 980.32m | 339.00 | -- | 6.37 | 1,672.91 | 16.69 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Viridian Therapeutics Inc | 314.00k | -237.73m | 982.87m | 96.00 | -- | 3.53 | -- | 3,130.15 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Petro Usa Inc | 0.00 | -33.38k | 1.00bn | -- | -- | -- | -- | -- | -0.0002 | -0.0002 | 0.00 | -0.0008 | 0.00 | -- | -- | -- | -19,074.29 | -192,120.00 | -- | -- | -- | -- | -- | -- | -- | -118.21 | -- | -- | -- | -- | -81.58 | -- | -- | -- |
Silence Therapeutics plc | 35.17m | -53.46m | 1.02bn | 116.00 | -- | 37.00 | -- | 29.07 | -0.4913 | -0.4913 | 0.3225 | 0.2162 | 0.2527 | -- | 94.73 | 303,231.10 | -38.40 | -43.18 | -47.88 | -53.35 | 54.24 | -- | -151.98 | -422.12 | -- | -15.11 | 0.0155 | -- | 40.97 | 305.31 | -2.74 | -- | 149.02 | -- |
Holder | Shares | % Held |
---|---|---|
Caligan Partners LPas of 31 Dec 2023 | 10.36m | 13.63% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.18m | 4.19% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.76m | 3.63% |
Kynam Capital Management LPas of 31 Dec 2023 | 2.70m | 3.55% |
Findell Capital Management LLCas of 31 Dec 2023 | 2.09m | 2.74% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.04m | 1.37% |
Vestal Point Capital LPas of 31 Dec 2023 | 1.03m | 1.35% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 978.87k | 1.29% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 959.17k | 1.26% |
Eversept Partners LPas of 31 Dec 2023 | 688.93k | 0.91% |